Advertisement

Lung

, Volume 193, Issue 1, pp 25–30 | Cite as

Serum Surfactant Protein D (SP-D) is a Prognostic Marker of Poor Outcome in Patients with A/H1N1 Virus Infection

  • Carlos Delgado
  • Edgar Krötzsch
  • Luis A. Jiménez-Alvarez
  • Gustavo Ramírez-Martínez
  • Jose E. Márquez-García
  • Alfredo Cruz-Lagunas
  • Juan Morán
  • Cármen Hernández
  • Patricia Sierra-Vargas
  • Federico Avila-Moreno
  • Carina Becerril
  • Martha Montaño
  • José L. Bañales-Méndez
  • Joaquín Zúñiga
  • Ivette Buendía-Roldán
Article

Abstract

Introduction

Surfactant protein D (SP-D) plays an important role in the innate responses against pathogens and its production is altered in lung disorders.

Methods

We studied the circulating levels of SP-D in 37 patients with acute respiratory distress syndrome due to the A/H1N1 virus infection and in 40 healthy controls. Cox logistic regression models were constructed to explore the association of SP-D levels and risk of death.

Results

Mortality rate after a 28-day was 32.42 %. Significant higher levels of SP-D were detected in A/H1N1 patients with fatal outcome (p < 0.05). After adjusting for confounding variables, levels of SP-D ≥250 ng/mL were associated with increased the risk of death (HR = 8.27, 95 % CI 1.1–64.1, p = 0.043).

Conclusions

Our results revealed that higher circulating levels of SP-D are associated with higher mortality risk in critically ill A/H1N1 patients. SP-D might be a predictive factor of poor outcomes in viral pneumonia.

Keywords

Surfactant protein D (SP-D) A/H1N1 virus Influenza ARDS Mortality Biomarker 

Notes

Acknowledgments

The authors thanks to the patients for their participation in this study. This study was supported by a Grant No. 127002 of the “Fondo Sectorial de Investigación en Salud y Seguridad Social” (FOSISSS) from the National Council of Science and Technology of Mexico (CONACYT).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Meunier I, Pillet S, Simonsen JN, Von Messling V (2010) Influenza pathogenesis: lessons earned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Crit Care Med 38:e21–e29. doi: 10.1097/CCM.0b013e3181c8b4d5 PubMedCrossRefGoogle Scholar
  2. 2.
    Shinde V, Bridges CB, Uyeki TM et al (2009) Triple-reassortant swine influenza A (H1), in humans in the United States, 2005–2009. N Engl J Med 360:2616–2625. doi: 10.1056/NEJMoa0903812 PubMedCrossRefGoogle Scholar
  3. 3.
    Perez-Padilla R, De la Rosa-Zamboni D, Ponce de León S et al (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 361:680–689. doi: 10.1056/NEJMoa0904252 PubMedCrossRefGoogle Scholar
  4. 4.
    Bermejo-Martin JF, Martin-Loeches I, Rello J et al (2010) Host adaptive immunity deficiency in severe pandemic influenza. Crit Care 14:R167. doi: 10.1186/cc9259 PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Lee N, Wong CK, Chan PK et al (2011) Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One 6:e26050. doi: 10.1371/journal.pone.0026050 PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Bautista E, Arcos M, Jimenez-Alvarez L et al (2013) Angiogenic and inflammatory markers in acute respiratory distress syndrome and renal injury associated to A/H1N1 virus infection. Exp Mol Pathol 94:486–492. doi: 10.1016/j.yexmp.2013.03.007 PubMedCrossRefGoogle Scholar
  7. 7.
    Crouch E (2000) Surfactant protein D and pulmonary host defense. Respir Res 1:93–108. doi: 10.1186/rr19 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Hartshorn K, White M, Tecle T, Sorensen G, Holmskov U, Crouch E (2010) Viral aggregating and opsonizing activity in collectin trimers. Am J Physiol Lung Cell Mol Physiol 298:L79–L88. doi: 10.1186/rr19 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Gallo R, Nizet V (2008) Innate barriers against infection and associated disorders. Drug Discov Today 5:145–152. doi: 10.1016/j.ddmec.2008.04.009 CrossRefGoogle Scholar
  10. 10.
    Pastva A, Wright J, Williams K (2007) Immunomodulatory roles of surfactant proteins A and D. Implications in lung disease. Proc Am Thor Soc 4:252–257. doi: 10.1513/pats.200701-018AW CrossRefGoogle Scholar
  11. 11.
    Greene K, Wright J, Steinberg K (1999) Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 160:1843–1850. doi: 10.1164/ajrccm.160.6.9901117 PubMedCrossRefGoogle Scholar
  12. 12.
    Winkler C, Atochina-Vasserman E, Holz O et al (2011) Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res 12:29. doi: 10.1186/1465-9921-12-29 PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Bernard GR, Artigas A, Brigham KL et al (1994) The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trials coordination. Am J Respir Crit Care Med 149:818–824. doi: 10.1164/ajrccm.149.3.7509706 PubMedCrossRefGoogle Scholar
  14. 14.
    Honda Y, Kuroki Y, Matsuura E et al (1995) Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152:1860–1866. doi: 10.1164/ajrccm.152.6.8520747 PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang L, Ikegami M, Korfhagen T (2006) Neither SP-A nor NH2-terminal domains of SP-A can substitute for SP-D in regulation of alveolar homeostasis. Am J Physiol Lung Cell Mol Physiol 291:L181–L190. doi: 10.1152/ajplung.00015.2006 PubMedCrossRefGoogle Scholar
  16. 16.
    Takahashi H, Kuroki Y, Tanaka H et al (2000) Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 162:258–263. doi: 10.1164/ajrccm.162.1.9903014 PubMedCrossRefGoogle Scholar
  17. 17.
    Greene K, King T Jr, Juroki Y et al (2002) Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 19:439–446. doi: 10.1183/09031936.02.00081102 PubMedCrossRefGoogle Scholar
  18. 18.
    Sin D, Leung R, Gan W, Man S (2007) Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 7:13. doi: 10.1186/1471-2466-7-13 PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Nishida S, Fukazawa R, Imai T et al (2011) Serum KL-6 and surfactant protein D in children with 2009 pandemic influenza infection. Pediatr Int 53:910–914. doi: 10.1111/j.1442-200X.2011.03398.x PubMedCrossRefGoogle Scholar
  20. 20.
    Boonarkart CH, Suptawiwat O, Uiprasertkul M et al (2012) A reduced expression of surfactant protein D in the lungs of fatal influenza H1N1 cases in 2009. Acta Virol 56:253–255. doi: 10.4149/av_2012_03_253 PubMedCrossRefGoogle Scholar
  21. 21.
    Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC (2009) Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vascul Diffus Lung Dis 26:155–161Google Scholar
  22. 22.
    Ware LB, Koyama T, Zhao Z et al (2013) Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care 17:R253. doi: 10.1186/cc13080 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Determann RM, Royakkers AA, Haitsma JJ et al (2010) Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med 10:6. doi: 10.1186/1471-2466-10-6 PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Pan T, Nielsen LD, Allen MJ et al (2002) Serum SP-D is a marker of lung injury in rats. Am J Physiol Lung Cell Mol Physiol 282:L824–L832. doi: 10.1152/ajplung.00421.2000 PubMedCrossRefGoogle Scholar
  25. 25.
    Eisner MD, Parsons P, Matthay MA et al (2003) Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 58:983–988. doi: 10.1136/thorax.58.11.983 PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Aono Y, Ledford JG, Mukherjee S et al (2012) Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185:525–536. doi: 10.1164/rccm.201103-0561OC PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Zúñiga J, Torres M, Romo J et al (2011) Inflammatory profiles in severe pneumonia associated with the pandemic influenza A/H1N1 virus isolated in Mexico City. Autoimmunity 44:562–570. doi: 10.3109/08916934.2011.592885 PubMedCrossRefGoogle Scholar
  28. 28.
    Ramírez-Martínez G, Cruz-Lagunas A, Jiménez-Alvarez L et al (2013) Seasonal and pandemic influenza H1N1 viruses induce differential expression of SOCS-1 and RIG-I genes and cytokine/chemokine production in macrophages. Cytokine 62:151–159. doi: 10.1016/j.cyto.2013.01.018 PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Kim SH, Hong SB, Yun SC et al (2011) Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 183:1207–1214. doi: 10.1164/rccm.201101-0110OC PubMedCrossRefGoogle Scholar
  30. 30.
    Martin-Loeches I, Lisboa T, Rhodes A et al (2011) Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 37:272–283. doi: 10.1007/s00134-010-2078-z PubMedCrossRefGoogle Scholar
  31. 31.
    Quispe-Laime AM, Bracco JD, Barberio PA et al (2010) H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 36:33–41. doi: 10.1007/s00134-009-1727-6 PubMedCrossRefGoogle Scholar
  32. 32.
    Annane D, Sébille V, Charpentier C et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871. doi: 10.1001/jama.288.7.862 PubMedCrossRefGoogle Scholar
  33. 33.
    Li XW, Jiang RM, Guo JZ (2003) Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report. Chin J Intern Med 42:378–381Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Carlos Delgado
    • 1
  • Edgar Krötzsch
    • 2
  • Luis A. Jiménez-Alvarez
    • 3
  • Gustavo Ramírez-Martínez
    • 3
  • Jose E. Márquez-García
    • 3
  • Alfredo Cruz-Lagunas
    • 3
  • Juan Morán
    • 3
  • Cármen Hernández
    • 3
  • Patricia Sierra-Vargas
    • 3
  • Federico Avila-Moreno
    • 4
  • Carina Becerril
    • 3
  • Martha Montaño
    • 3
  • José L. Bañales-Méndez
    • 3
    • 5
  • Joaquín Zúñiga
    • 3
  • Ivette Buendía-Roldán
    • 3
    • 6
  1. 1.Surgical Intensive Care Unit, Centro Médico Nacional “20 de Noviembre”ISSSTEMexico CityMexico
  2. 2.Connective Tissue Laboratory, Centro Nacional de Investigación y Atención de QuemadosInstituto Nacional de RehabilitaciónMexico CityMexico
  3. 3.Instituto Nacional de Enfermedades Respiratorias Ismael Cosío VillegasMexico CityMexico
  4. 4.FES-Iztacala, Unidad de Biomedicina, UBIMED, Universidad Nacional Autónoma de MéxicoMexico CityMexico
  5. 5.Instituto Nacional de Cardiología Ignacio ChávezMexico CityMexico
  6. 6.Research UnitInstituto Nacional de Enfermedades RespiratoriasMexico CityMexico

Personalised recommendations